AngioDynamics' (ANGO) Sell (D-) Rating Reiterated at Weiss Ratings

Key Points

• AngioDynamics (ANGO) received a "sell (D-)" rating from Weiss Ratings, despite being positively rated by some other analysts who have set price targets ranging from $16.00 to $24.00.
• In the latest earnings report, AngioDynamics reported a quarterly revenue of $75.71 million and an EPS of ($0.10), beating estimates and showing a 12.1% increase in revenue year-over-year.
• Insider trades indicate confidence in the company's future, as CEO James C. Clemmer purchased 10,000 shares at a total cost of approximately $111,500 recently.

AngioDynamics (NASDAQ:ANGO - Get Free Report)'s stock had its "sell (d-)" rating reiterated by investment analysts at Weiss Ratings in a report released on Friday,Weiss Ratings reports.

ANGO has been the topic of several other research reports. Canaccord Genuity Group upped their price objective on shares of AngioDynamics from $17.00 to $18.00 and gave the company a "buy" rating in a report on Friday, October 3rd. HC Wainwright reiterated a "buy" rating and set a $16.00 price objective on shares of AngioDynamics in a report on Wednesday, July 16th. Lake Street Capital began coverage on shares of AngioDynamics in a report on Wednesday, July 16th. They set a "buy" rating and a $24.00 price objective on the stock. Finally, Wall Street Zen lowered shares of AngioDynamics from a "buy" rating to a "hold" rating in a report on Saturday, October 4th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $19.33.

AngioDynamics Trading Up 2.8%

ANGO stock traded up $0.34 during midday trading on Friday, hitting $12.34. The stock had a trading volume of 632,356 shares, compared to its average volume of 603,634. The business has a fifty day moving average price of $10.71 and a two-hundred day moving average price of $9.92. AngioDynamics has a 1-year low of $6.57 and a 1-year high of $13.50. The firm has a market cap of $508.41 million, a P/E ratio of -15.82 and a beta of 0.78.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last announced its quarterly earnings data on Thursday, October 2nd. The medical instruments supplier reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.02. AngioDynamics had a negative net margin of 10.67% and a negative return on equity of 3.16%. The firm had revenue of $75.71 million for the quarter, compared to analyst estimates of $72.69 million. During the same quarter in the prior year, the business earned ($0.11) earnings per share. The business's quarterly revenue was up 12.1% compared to the same quarter last year. AngioDynamics has set its FY 2026 guidance at -0.330--0.230 EPS. On average, equities analysts anticipate that AngioDynamics will post -0.37 EPS for the current year.

Insider Transactions at AngioDynamics

In other AngioDynamics news, CEO James C. Clemmer bought 10,000 shares of the stock in a transaction that occurred on Thursday, October 9th. The shares were bought at an average price of $11.15 per share, for a total transaction of $111,500.00. Following the acquisition, the chief executive officer directly owned 882,529 shares of the company's stock, valued at approximately $9,840,198.35. The trade was a 1.15% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Lawrence T. Weiss bought 10,000 shares of the stock in a transaction that occurred on Tuesday, October 21st. The stock was acquired at an average price of $11.81 per share, for a total transaction of $118,100.00. Following the acquisition, the senior vice president directly owned 93,597 shares in the company, valued at $1,105,380.57. The trade was a 11.96% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased a total of 20,890 shares of company stock worth $239,532 in the last 90 days. 6.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On AngioDynamics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ANGO. Divisadero Street Capital Management LP increased its stake in AngioDynamics by 253.7% in the 2nd quarter. Divisadero Street Capital Management LP now owns 3,395,430 shares of the medical instruments supplier's stock valued at $33,683,000 after buying an additional 2,435,365 shares during the last quarter. Armistice Capital LLC increased its stake in AngioDynamics by 140.1% in the 1st quarter. Armistice Capital LLC now owns 2,094,000 shares of the medical instruments supplier's stock valued at $19,663,000 after buying an additional 1,222,000 shares during the last quarter. Nuveen LLC purchased a new stake in AngioDynamics in the 1st quarter valued at about $10,803,000. Bastion Asset Management Inc. bought a new position in shares of AngioDynamics during the 1st quarter valued at approximately $6,601,000. Finally, AIGH Capital Management LLC bought a new position in shares of AngioDynamics during the 1st quarter valued at approximately $4,455,000. Hedge funds and other institutional investors own 89.43% of the company's stock.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.